Financing
Earendil Labs raises $787M — a China-rooted “AI biotech” talks up a possible IPO
Endpoints reports that Earendil Labs has pulled in $787 million in financing as it gears up for what it frames as a possible IPO path. The company sits at the messy intersection of drug discovery, AI compute, and cross-border biotech capital — which means the story isn’t just “big round,” it’s also “how investable is the platform when geopolitics are the background radiation.” The hard part will be showing that the AI stack translates into clinical leverage (better hit rates, faster timelines), not just prettier charts. If they can point to concrete assets with clear endpoints (INDs / Phase 1 starts), the size of the raise stops being a curiosity and becomes a signal.
Source: Endpoints News